Clinical trials: Opioid Withdrawal
Opioid-Related Disorders, Dependency (Psychology)
Buspirone for Opioid Tapering
This is a pilot study to collect preliminary data to support a grant application. The goal of the study is to evaluate whether the Food and Drug Administration (FDA)-approved and generically-available medication buspirone reduces…
- Conditions
- Opioid-Related Disorders, Dependency (Psychology), Pain, Chronic, Opiate Withdrawal Syndrome
- Trial name
- NCT03521960
- Testing
- Buspirone oral capsule
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Substance Withdrawal Syndrome
The Effect of Valproate on Benzodiazepine Withdrawal Severity
The aim of this study is to determine whether valproate is effective in the treatment of benzodiazepine withdrawal symptoms in subjects receiving maintenance treatment for opiate dependence.
- Trial name
- NCT00570219
- Testing
- valproate
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- University of Helsinki
Opioid Withdrawal, Opioid Use Disorder
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
The primary objective of this trial is to measure changes in physiologic signals to quantify the status of the autonomic nervous system during opioid withdrawal and cravings.
- Trial name
- NCT06487533
- Testing
- EmbracePlus Smartwatch, Corti Sensor
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Spark Biomedical, Inc.
Opioid Use Disorder
Cannabis and Opioid Use Disorder
This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.
- Trial name
- NCT05729932
- Testing
- Inhaled vaporized cannabis, Intransal opioid
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Shanna Babalonis, PhD
Opioid-Related Disorders
Pioglitazone to Treat Opioid Withdrawal Symptoms
Background: Opioid-withdrawal symptoms include runny nose, body aches, chills, sweating, and diarrhea. Many people have these symptoms when trying to stop using opioid drugs.
- Trial name
- NCT01517165
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-use Disorder, Opioid Withdrawal
Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
Clinical performance data for transcutaneous auricular neurostimulation (tAN) as a method to aid in the reduction of symptoms associated with opioid withdrawal in order to support clinical substantial equivalence to a predicate…
- Trial name
- NCT04075214
- Testing
- transcutaneous auricular neurostimulation (tAN)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Spark Biomedical, Inc.
Opioid Dependence
Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low.
- Trial name
- NCT00447564
- Testing
- Probuphine
- Where
- 18 sites in United States
- Volunteers
- 163 people
- Sponsor
- Titan Pharmaceuticals
Opioid Dependence, Opioid Withdrawal
Medical Management of Sleep Disturbance During Opioid Tapering
This study will evaluate whether a dual orexin-receptor antagonist approved by the FDA for sleep disturbance, suvorexant (SUVO; Belsomra), will increase total sleep time in patients with opioid use disorder (OUD) undergoing…
- Conditions
- Opioid Dependence, Opioid Withdrawal, Sleep Disturbance
- Trial name
- NCT03789214
- Testing
- Low Dose Suvorexant, High Dose Suvorexant
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Opioid Withdrawal, Analgesia
Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain
The purpose of the study is to find out how a stimulation device worn on the ear works. This device is thought to stimulate nerves in the area around the ear to change the signals in the brain.
- Trial name
- NCT05555485
- Testing
- transcutaneous Auricular neurostimulation - Active
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Neonatal Abstinence Syndrome
Buprenorphine for the Treatment of Neonatal Abstinence Syndrome
Neonatal abstinence syndrome is a disease that affects children who were exposed to opioid drugs prior to birth. Commonly used treatments at present include morphine or tincture of opium.
- Trial name
- NCT00521248
- Testing
- buprenorphine, Oral morphine solution
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Thomas Jefferson University
Substance Withdrawal Syndrome
Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Mechanically ventilated critically ill adults may require prolonged administration of opioids to facilitate ventilator support and maintain comfort.
- Trial name
- SOWA-ICU (NCT03435614)
- Testing
- Opioids
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Marc M. Perreault
Opioid Dependence
Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low.
- Trial name
- PRO-807 (NCT00630201)
- Testing
- Probuphine (buprenorphine implant)
- Where
- 15 sites in United States
- Volunteers
- 62 people
- Sponsor
- Titan Pharmaceuticals
Substance Use Disorders, Opiate Dependence
The Effect of Self-Forgiveness on Self-Stigma in Addiction.
This study has an experimental design and will examine the difference in pre-test and post-test data on the Self-Forgiveness Dual Process Scale (SFDPS) (Griffin, Worthington, Davis, Hook, \& Maguen, 2018) and the Substance Abuse…
- Conditions
- Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder
- Trial name
- NCT03971097
- Testing
- Six Step Model of Self-Forgiveness, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Pittsburgh
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients
The primary objective of this study is to assess lofexidine related effects on QTc (an interval of the heart rhythm) in subjects receiving buprenorphine maintenance.
- Trial name
- NCT01820442
- Testing
- Lofexidine HCl, Lofexidine-matching sugar pill
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Cancer Pain, Cancer
PARASTOP - Paracetamol With Strong Opioids
Current guidelines recommend all people with cancer-related pain should be prescribed paracetamol, even those receiving high doses of strong pain killers (opioids) such as morphine.
- Trial name
- PARASTOP (NCT05051735)
- Testing
- Paracetamol
- Where
- 15 sites in Italy, Norway and 2 more
- Volunteers
- 204 people
- Sponsor
- Oslo University Hospital
Opioid Withdrawal (Disorder)
Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal
Stopping prescription opioid pain medications can be difficult due to withdrawal symptoms. This study will test if LUCEMYRA helps reduce withdrawal symptoms and helps more people reduce their opioid dose compared to placebo.
- Trial name
- TAPER (NCT04070157)
- Testing
- Lofexidine
- Where
- 12 sites in United States
- Volunteers
- 4 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Opioid Use Disorder
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
This study is examining the use of Tezampanel (TZP) for treatment of Opioid Withdrawal Syndrome (OWS) in participants with Opioid Use Disorder (OUD).
- Trial name
- NCT06538558
- Testing
- Tezampanel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Proniras Corporation
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
Randomized pilot trial comparing scheduled morphine dosing with a weaning protocol to intermittent morphine dosing on an as-needed basis for newborns with neonatal abstinence syndrome.
- Conditions
- Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome
- Trial name
- NCT04298853
- Testing
- Morphine PRN, Morphine scheduled
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Indiana University
Opioid Withdrawal, Opioid-use Disorder
Buprenorphine in the Emergency Department
This is a pilot randomized control trial randomizing patients presenting in opioid withdrawal to the emergency department to receive either one of clonidine (usual standard of care) or buprenorphine for their opioid withdrawal.
- Trial name
- BED (NCT03174067)
- Testing
- Buprenorphine, Clonidine
- Volunteers
- 26 people
- Sponsor
- St. Joseph's Health Centre Toronto
Opioid-Related Disorders
Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10
The purpose of this study is to assess the safety of lofexidine in the treatment of opiate-dependent individuals.
- Trial name
- NCT00000345
- Testing
- Lofexidine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)